[Flupirtine in chronic myofacial pain conditions].
With respect to its molecular structure, mechanisms of action and the profile of action and side effects, Flupirtine is an innovative drug. It can be clearly distinguished from acetylsalicylic acid or NSAIDs on the one hand, and opioids on the other. Clinical observations and animal experiments have provided evidence for a muscle-relaxing effect. On the basis of this knowledge, an open prospective trial was conducted in 50 patients suffering from chronic myofascial pain. In 35 of these patients (70%), daily doses within the range 300-400 mg, individually 600 mg, resulted in definitive amelioration of pain. 17 patients developed side effects, namely somnolence, dizziness and rarely vomiting. In 3 patients, the side effects disappeared when the dose was reduced, the analgesic effect being preserved. On the basis of the data obtained to date, Flupirtine would appear to represent a new possibility for treating pain.
Wörz
R
R
Schmerzzentrum Bad Schönborn.
D000328:Adult; D000368:Aged; D000631:Aminopyridines / Q000627:therapeutic use*; D000700:Analgesics; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009209:Myofascial Pain Syndromes / Q000188:drug therapy*; D011446:Prospective Studies
D000631:Aminopyridines; D000700:Analgesics; C034161:flupirtine
Flupirtin bei chronischen myofasziellen Schmerzzuständen.